Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership
Summary
None Allogenica received a 2.5 million grant from the French governments France 2030 program to support the industrialization of its breakthrough universal CAR-T therapies for blood cancers. None With this funding, Allogenica will collaborate with strategic partners across the 100% French ecosystem to establish a cutting-edge CAR-T biomanufacturing by 2026, strengthening Frances global leadership position and driving economic growth and job creation. This prestigious funding will help accelerate the industrialization of Allogenicas lead-candidate CAR-T, called the XL-001, making them safer, more accessible, and cost-effective, primarily for patients with leukemia and lymphoma. This grant is part of a selective initiative, with Allogenica standing out as one of the few companies entrusted with this strategic support, underscoring its significant role in the biotherapy sector. Through strategic collaborations with key French biomanufacturing and preclinical partners, the company is building a robust manufacturing chain for allogeneic CAR-T therapies.